Colombovac® PMV
Active substance
ATC code
Species
Pigeons
Indications
For the active immunisation of pigeons to prevent mortality and clinical signs due to infection with paramyxovirus serotype 1 infection.
Onset of immunity: one month after inoculation
Duration of immunity: 12 months.
Dose to be administered and administration route
Dose: One dose (0.2 ml) per pigeon.
Administration: The vial has to be swirled several times before use.
The vaccine has to be administered by subcutaneous injection dorsally in the neck region (in the direction of the back).
Primary vaccination:
Racing pigeons
All birds in the loft should be given one vaccination annually not less than 14 days before the beginning of the racing season.
Young birds may be vaccinated with Colombovac PMV from 3 weeks of age when a single injection will provide immunity for 1 year.
Following vaccination avoid contact with birds from other lofts for at least 14 days.
Show Pigeons
All birds on the premises should be given one vaccination annually not less than 14 days before the beginning of the show season.
Young birds may be vaccinated with Colombovac PMV from 3 weeks of age when a single injection will provide immunity for 1 year. Following vaccination, avoid contact with birds from other sources for at least 14 days.
Booster vaccination:
Racing pigeons
All adult birds in the loft should be given a single booster vaccination annually. Where the annual booster vaccination may interfere with the training or racing programme, it may be brought forward prior to the commencement of each racing season.
Show Pigeons
All adult birds on the premises should be given a single booster vaccination annually.
Adverse reactions
A transient swelling at the injection site of up to approximately 1 cm in diameter may occur very commonly, which may last up to 4 weeks or more. Swellings
normally tend to disappear without treatment. In cases of adverse reactions not disappearing spontaneously the veterinary surgeon should be contacted.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
